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In non-muscle cells the mechanism by which microfilament bundles interact with the plasma membrane is 
unclear, Vinculin. a 130 kDa protein found in adhesion plaques, has been postulated to have a role as a 
membrane anchor for microfilaments and we have investigated the biochemistry of this molecule in more 
detail. We report that a fraction of vinculin in chick embryo fibroblasts is acylated by myristic acid. This 
modifi~dtion was present in both membrane-bound, cytoskeletal and cytosolic vinculin and thus did not 
determme preferential subcellular localisation. Myristic acid was also present in vinculin from cells trans- 
formed by Rous sarcoma virus. 
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1. INTRODUCTION 
In recent years much attention has focussed on 
the interaction of the actin-containing microfila- 
ment system with the plasma membrane, and while 
the membrane cytoskeleton in erythrocytes is now 
well documented, the situation is less clear in other 
cells whose cytoskeletal apparatus appears to be in 
a more dynamic state. One of the candidates for a 
protein which anchors microfilaments to the mem- 
brane is vinculin, a 130 kDa protein present in the 
adhesion plaques of many cells and at cell-cell 
junctions [l-4] and it has been proposed that 
tyrosine-specific phosphorylation of vinculin in 
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RSV-transformed cells leads to a disruption of this 
function, thus resulting in the rounded mor- 
phology characteristic of cells transformed by RSV 
[5,6]. The paucity of biochemical information 
about vinculin has led us to examine in more detail 
biochemical and functional aspects of this 
molecule in an attempt to gain an insight into the 
mechanism by which vinculin might interact with 
the membrane cytoskeleton. 
2. MATERIALS AND METHODS 
2.1. Cells 
Chick embryo fibroblasts were grown in DMEM 
supplemented with 10% tryptose phosphate broth, 
5% newborn calf serum and 1% chick serum, and 
transformed by Prague C strain RSV as described 
171. 
2.2. Radioiabelling and immune precipitation 
CEF were labelled for 3 h with 50pCi/ml 
[3sS]methionine or 10 j&i/ml [‘4C]myristate 
(Amersham) in serum-free DMEM containing 
5 mM sodium pyruvate. After iabelling the cells 
were washed and either directly lysed in SDS sam- 
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ple buffer, or lysed in RIPA buffer and immune 
precipitated using a rabbit anti-vinculin serum [8], 
followed by separation by SDS-PAGE. The gels 
were then prepared for fluorography using 
EN3HANCE (Amersham) as described by the 
manufacturer. 
2.3. Cell fractionation 
A crude membrane fraction was obtained by 
hypotonic swelling followed by dounce 
homogenisation. After low-speed centrifugation to 
remove nuclei the homogenates were centrifuged at 
30000 x g for 30 min to obtain a crude membrane 
fraction (pellet) and cytosolic fraction (superna- 
tant) [7]. Cytoskeletons were prepared by the 
method of Ben-Ze’ev et al. [9]. Labelled cells were 
extracted in CSK buffer (10 mM Mes, pH 6.8, 
100 mM KCl, 300 mM sucrose, 2.5 mM MgClz, 
1 mM CaC12, 1% NP40, 2 mM PMSF) for 5 min, 
washed twice in CSK buffer and the insoluble 
‘cytoskeleton’ dissolved in RIPA buffer. An equal 
volume of double-strength RIPA buffer was added 
to the soluble fraction and these were then sub- 
jected to immune precipitation. 
2.4. Hydroxylamine treatment 
The gel was placed in 1 M hydroxylamine (pH 
8.5) or 0.1 M Tris (pH 8.5) for 2 h at room 
temperature. After washing, the gels were re-fixed 
and prepared for fluorography. 
2.5. Lipid analysis 
The [ 14C]myristate-labelled vinculin band was 
excised and hydrolysed with 6 N HCl under 
nitrogen for 18 h at 110°C. The hydrolysate was 
extracted twice with benzene, the organic phase 
dried under NZ and the fatty acids separated by 
thin-layer chromatography on KC18 reversed- 
phase plates in acetic acidiacetonitrile [lo]. 0.5 cm 
sections were scraped into Aquasol and counted. 
Authentic palmitic acid and myristic acid were 
used as standards. 
3. RESULTS 
When CEF were labelled with [14C]myristicacid 
and the resultant proteins separated by SDS- 
PAGE, a series of labelled bands distinct from that 
seen with [35S]methionine-labelled cells were ap- 
parent, with molecular masses ranging from 30 to 
180 kDa (fig.1). We were particularly interested in 
the myristylated band of 130 kDa, since previous 
work has shown that vinculin has this apparent 
molecular mass. The identity of this band with vin- 
culin was confirmed by immune precipitation of 
vinculin from [ 14C]myristate- or [35S]methionine- 
labelled CEF. SDS-PAGE revealed [‘4C]myristate- 
labelled band specifically precipitated by a rabbit 
anti-vinculin antiserum which co-migrated with 
35S-labelled vinculin (fig.1). The specificity of the 
lipid linked to vinculin was examined by compar- 
ing vinculin precipitated from cells labelled with 
either [i4C]myristate or [‘4C]palmitate (fig.2). 
Quantitation revealed that vinculin from 
palmitate-labelled CEF contained only 23% of the 
counts of vinculin from myristate-labelled CEF. 
This [14C]myristate label was resistant o treatment 
with hydroxylamine (fig.2). To ascertain that the 
label was lipid, [14C]myristate-labelled vinculin 
was excised from the gel after SDS-PAGE and the 
lipids released by acid hydrolysis were analysed. 
The major labelled lipid present co-migrated with 
authentic myristic acid, however some palmitic 
acid was detected (fig.3), and also a peak represen- 
ting some unknown lipid which migrated more 
slowly than either myristate or palmitate. From 
scintillation counting of [14C]myristate-labelled 
vinculin and protein determination of stained gels 
it was estimated that the stoichiometry of 
lipid/protein was 0.04, suggesting only 4% of vin- 
culin molecules in the cell contain lipid. However, 
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Fig.1. Immune precipitation of vinculin from 
[35S]methionine- or [‘4C]myristate-labelled CEF. Lanes: 
1,2, total protein; 3-6, immune precipitation; P, pre- 
immune serum; V, anti-vinculin serum. 
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Fig.2. Comparison of myristate and palmitate Iabehing 
of vinculin and stability to hydroxylamine. Lanes: 1, 
anti-vinculin, [14C]myristate; 2, pre-immune, [‘4C]my- 
ristate; 3, [r4C]palmitate anti-vinculin; 4, [r4C]myristate 
me-immune, buffer treated; 5, [14~]myristate anti- 
vincuhn, buffer treated; 6, [‘4Clmyristate, pre-immune 
hydroxylamine treated; 7, [‘4C]myristate anti-vincufin, 
hydroxylamine treated. 
this may be an underestimate since over a 3 h 
labelling period it is unlikely that the protein will 
be labelled to equilibrium. We were interested in 
whether myristate-containing vinculin showed a 
preferential localisation to any particular cellular 
fraction. When CEF were fractionated into crude 
membrane and cytosolic fractions, the proportion 
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Fig.3. Identification of fatty acids liberated after 
hydrolysis of ~14C]myristate-~abelIed vincuhn. 
Fig.4. Immune precipitation 
March 1987 
of r35SJmeth~oni~e- or 
[ “C]myristate-IabelIed vinculin from crude membrane 
and cytosohc fractions (lanes l-4) or cytoskeletai and 
soluble fractions (lanes S-8); m, crude membranes; c, 
cytosolic; csk, cytoskeleton; sol, detergent-soluble. 
of ~14C]my~istate-labelled vinculin in each com- 
partment closely resembled that of [35S]methio- 
nine-labelled vinculin, with approx. 10% of the 
vinculin in the crude membrane fraction and 90% 
in the cytosol (fig.4). Labetled CEF were also ex- 
tracted into a c~oskeletal-associated fraction and 
a deter~ent*soiuble fraction by published pro- 
cedures [9,11]. The proportions of [*4C]myristate- 
labelled vinculin in each fraction were also very 
similar to that of [3JS]methionine-labelled vin- 
culin, with about 90010 freely soluble and 10% 
cytoskeletal (fig.4); these proportions are similar 
to that of vinculin in human platelets [12]. Thus, 
myristylation of vinculin does not determine 
preferential localisation to a membrane or 
cytoskeletal fraction, 
Since the localisation of vincutin is drastically 
affected by transformation, we determined the ex- 
tent of myristylation of vinculin in RSV- 
transformed CEF to examine whether there was 
any change in the amount of Iipid associated. RSV- 
transformed CEF contained about 60-70010 of the 
vinculin of untransformed cells as ascertained by 
[35S]methionine labelling, however there was a 
comparable reduction in the amount of 
~14C]myrist~te-labelled vinculin in RSV-trans- 
formed cells, thus the stoi~hiometry of lipid to pro- 
tein remained constant (fig.5). 
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Fig.5. Vinculin from untransformed (lanes 1,2,5,6) and 
RSV-transformed (lanes 3,4,7,8) CEF. Cells were 
labelled with [35S]methionine (lanes l-4) or 
[‘4C]myristate (lanes 5-8). P, pre-immune serum; V, 
anti-vinculin. 
4. DISCUSSION 
A function for the cytoskeletal protein vinculin 
has yet to be elucidated, and a study of the 
biochemical properties of this protein may provide 
an insight into this problem. Our findings that a 
proportion of vinculin is myristylated suggest hat 
this molecule has the potential to interact with 
membranes, although our fractionation ex- 
periments do not support this. It may be that this 
interaction is not stable under the conditions 
employed, and that other factors are important. 
Myristylation is necessary for the attachment of 
pp60” - ‘*’ to the plasma membrane since mutant 
proteins lacking myristate are largely cytoplasmic 
[13], although additional factors may also be in- 
volved in this localisation [17]. Calcineurin B [14] 
and the CAMP-dependent protein kinase catalytic 
subunit [ 151 contain myristic acid yet are 
cytoplasmic, so it is clear that myristylation per se 
is not sufficient for membrane localisation. Some 
membrane-associated components such as p21 of 
Harvey murine sarcoma virus and transferrin 
receptor have been shown to contain another lipid 
modification, addition of palmitic acid [ 16,171, 
and it is of interest to note that in erythrocytes the 
membrane-cytoskeletal component ankyrin has 
been reported to contain palmitic acid [ 181. The at- 
tachment of myristic acid to other proteins has 
been shown to be mediated via an amide bond 
formed between N-terminal glycine and myristate 
[13] and it may be that a similar bond is involved 
here since the bond is stable to hydroxylamine 
treatment, although the amino acid sequence of 
vinculin has not yet been determined. Consistent 
with this is the finding that the amino-terminus of 
vinculin is blocked when amino acid sequencing of 
the protein is attempted (Critchley, D.R., personal 
communication). 
Apart from its cellular localisation there is no 
functional evidence to support a membrane anchor 
role for vinculin, since vinculin does not act as an 
actin-binding protein [19,20], and has not been 
found in purified plasma membranes of HeLa cells 
[20]. However, under appropriate conditions vin- 
culin can associate with plasma membranes in- 
dependently of actin [21,22] and Burridge and 
co-workers have described the interaction of vin- 
culin with another protein, talin [23], which in turn 
may interact with the cell membrane receptor for 
fibronectin [24]. Furthermore, binding ex- 
periments and crosslinking-labelling experiments 
have shown that vinculin will incorporate into syn- 
thetic lipid bilayers containing acidic phos- 
pholipids and that incorporation of a 
photoactivatable 3H-labelled lipid component 
under these conditions results in the labelling of 
vinculin [25,26]. Thus, given the proper conditions 
vinculin might interact with the plasma membranes 
of cells and tightly associate with lipid domains in 
the membrane. The finding that PDGF-stimulated 
reorganisation of vinculin in epithelial cells is 
abrogated by inhibitors of phospholipase would 
also suggest hat a lipid moiety associated with vin- 
culin might be functionally important (271. 
Myristylation may provide a means to mediate this 
phenomenon. 
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